A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of ...
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...
I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...
Novo Nordisk (NVO) reported headline results from STEP UP, a phase 3b trial in the global STEP programme. The trial achieved primary ...